Grail, Inc.-Grail Stock Plunges 50% After Earnings. But It's These Test Results That Are to Blame.

Grail Stock Plunges 50% After Earnings. But It's These Test Results That Are to Blame.

Galleri多癌种筛查试验关键结果 - 该生物技术公司宣布其多癌种筛查测试Galleri在一项英国试验中未能在统计学上显著降低3期和4期癌症的发病率 [1] 试验结果解读 - 试验核心终点未达到即Galleri测试未能实现统计学上显著的晚期癌症减少 [1]

Grail, Inc.-Grail Stock Plunges 50% After Earnings. But It's These Test Results That Are to Blame. - Reportify